Envestnet Portfolio Solutions Inc. lessened its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 20.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,416 shares of the medical research company's stock after selling 2,696 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Natera were worth $1,649,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in shares of Natera by 205.4% in the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock valued at $355,493,000 after purchasing an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Natera by 3.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company's stock valued at $315,194,000 after purchasing an additional 85,236 shares during the period. Geode Capital Management LLC boosted its position in shares of Natera by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company's stock worth $265,747,000 after purchasing an additional 143,825 shares during the last quarter. Maverick Capital Ltd. grew its stake in shares of Natera by 25.2% during the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company's stock worth $170,119,000 after purchasing an additional 269,706 shares during the period. Finally, Castle Hook Partners LP increased its holdings in Natera by 27.4% in the third quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company's stock valued at $144,734,000 after purchasing an additional 245,505 shares during the last quarter. 99.90% of the stock is owned by institutional investors.
Natera Stock Down 3.1 %
Natera stock traded down $4.74 during mid-day trading on Wednesday, reaching $149.84. The company's stock had a trading volume of 1,091,690 shares, compared to its average volume of 1,336,917. The business's 50 day simple moving average is $160.70 and its 200 day simple moving average is $150.56. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The company has a market capitalization of $20.26 billion, a price-to-earnings ratio of -85.14 and a beta of 1.80.
Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. As a group, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.
Analyst Ratings Changes
NTRA has been the topic of a number of recent analyst reports. Canaccord Genuity Group restated a "buy" rating and set a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. Piper Sandler lifted their price objective on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, December 13th. BTIG Research reiterated a "buy" rating on shares of Natera in a report on Friday, February 28th. Finally, Morgan Stanley upped their price objective on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $178.12.
Get Our Latest Stock Analysis on Natera
Insider Transactions at Natera
In related news, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now owns 267,629 shares in the company, valued at approximately $44,150,756.13. This represents a 22.69 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Fesko sold 663 shares of Natera stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 306,797 shares of company stock worth $48,940,883 in the last 90 days. Corporate insiders own 7.60% of the company's stock.
About Natera
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Articles
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
